| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| SRPT - Sarepta Therapeutics Inc | BUY | 161 @ USD 18.67 | USD 3,006 | The ETF bought 161 new shares of SRPT (Sarepta Therapeutics Inc). The shares were bought for an average price of 18.67 compared to the previous average buy price of 34.5337. This is -45.9% lower than average price of previous purchases of SRPT. |
| TERN - Tern Plc | BUY | 145 @ USD 18.19 | USD 2,638 | The ETF bought 145 new shares of TERN (Tern Plc). The shares were bought for an average price of 18.19 compared to the previous average buy price of 5.12922. This is 254.6% higher than average price of previous purchases of TERN. |
| CSTL - Castle Biosciences Inc | BUY | 48 @ USD 33.57 | USD 1,611 | The ETF bought 48 new shares of CSTL (Castle Biosciences Inc). The shares were bought for an average price of 33.57 compared to the previous average buy price of 21.1566. This is 58.7% higher than average price of previous purchases of CSTL. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 4.69 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 4.69. The average price that ABCL shares were previous bought at was USD 3.9221. The current market price is 19.6% higher than average price they were purchased at. The value of the holding in ABCL has fallen by USD 34,365 compared to the previous valuation of Abcellera Biologics Inc |
| ABUS - Arbutus Biopharma Corp | HOLD | 0 @ USD 4.61 | USD 0 | The current share valuation price of ABUS based on adjusted close was USD 4.61. The average price that ABUS shares were previous bought at was USD 3.60358. The current market price is 27.9% higher than average price they were purchased at. The value of the holding in ABUS has increased by USD 13,722 compared to the previous valuation of Arbutus Biopharma Corp however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 22.33 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 22.33. The average price that ACAD shares were previous bought at was USD 20.789. The current market price is 7.4% higher than average price they were purchased at. The value of the holding in ACAD has increased by USD 52,521 compared to the previous valuation of ACADIA Pharmaceuticals Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| ACIU - AC Immune Ltd | HOLD | 0 @ USD 3.43 | USD 0 | The current share valuation price of ACIU based on adjusted close was USD 3.43. The average price that ACIU shares were previous bought at was USD 2.36395. The current market price is 45.1% higher than average price they were purchased at. The value of the holding in ACIU has increased by USD 8,304 compared to the previous valuation of AC Immune Ltd however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 87.51 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 87.51. The average price that ACLX shares were previous bought at was USD 71.5433. The current market price is 22.3% higher than average price they were purchased at. The value of the holding in ACLX has fallen by USD 23,970 compared to the previous valuation of Arcellx Inc |
| ADMA - ADMA Biologics Inc | HOLD | 0 @ USD 15.37 | USD 0 | The current share valuation price of ADMA based on adjusted close was USD 15.37. The average price that ADMA shares were previous bought at was USD 17.4539. The current market price is -11.9% lower than average price they were purchased at. The value of the holding in ADMA has increased by USD 114,512 compared to the previous valuation of ADMA Biologics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 17.59 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 17.59. The average price that ADPT shares were previous bought at was USD 11.7695. The current market price is 49.5% higher than average price they were purchased at. The value of the holding in ADPT has increased by USD 65,138 compared to the previous valuation of Adaptive Biotechnologies Corp however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| AGIO - Agios Pharm | HOLD | 0 @ USD 40.51 | USD 0 | The current share valuation price of AGIO based on adjusted close was USD 40.51. The average price that AGIO shares were previous bought at was USD 35.794. The current market price is 13.2% higher than average price they were purchased at. The value of the holding in AGIO has increased by USD 18,914 compared to the previous valuation of Agios Pharm however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| AKRO - Akero Therapeutics Inc | HOLD | 0 @ USD 54.05 | USD 0 | The current share valuation price of AKRO based on adjusted close was USD 54.05. The average price that AKRO shares were previous bought at was USD 49.1339. The current market price is 10.0% higher than average price they were purchased at. The value of the holding in AKRO has increased by USD 1,034 compared to the previous valuation of Akero Therapeutics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| ALEC - Alector Inc | HOLD | 0 @ USD 1.25499 | USD 0 | The current share valuation price of ALEC based on adjusted close was USD 1.25499. The average price that ALEC shares were previous bought at was USD 1.94702. The current market price is -35.5% lower than average price they were purchased at. The value of the holding in ALEC has fallen by USD 4,417 compared to the previous valuation of Alector Inc |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 31.07 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 31.07. The average price that ALKS shares were previous bought at was USD 30.3896. The current market price is 2.2% higher than average price they were purchased at. The value of the holding in ALKS has increased by USD 72,403 compared to the previous valuation of Alkermes Plc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| ALLO - Allogene Therapeutics Inc | HOLD | 0 @ USD 1.11 | USD 0 | The current share valuation price of ALLO based on adjusted close was USD 1.11. The average price that ALLO shares were previous bought at was USD 1.33658. The current market price is -17.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of Allogene Therapeutics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 434.56 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 434.56. The average price that ALNY shares were previous bought at was USD 372.91. The current market price is 16.5% higher than average price they were purchased at. The value of the holding in ALNY has increased by USD 929,564 compared to the previous valuation of Alnylam Pharmaceuticals Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| ALT - Altitude Group Plc | HOLD | 0 @ USD 3.75 | USD 0 | The current share valuation price of ALT based on adjusted close was USD 3.75. The average price that ALT shares were previous bought at was USD 5.20689. The current market price is -28.0% lower than average price they were purchased at. The value of the holding in ALT has fallen by USD 544 compared to the previous valuation of Altitude Group Plc |
| AMGN - Amgen Inc | HOLD | 0 @ USD 319.86 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 319.86. The average price that AMGN shares were previous bought at was USD 286.598. The current market price is 11.6% higher than average price they were purchased at. The value of the holding in AMGN has increased by USD 4,295,184 compared to the previous valuation of Amgen Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 13.24 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 13.24. The average price that AMLX shares were previous bought at was USD 6.81287. The current market price is 94.3% higher than average price they were purchased at. The value of the holding in AMLX has fallen by USD 28,484 compared to the previous valuation of Amylyx Pharmaceuticals Inc |
| AMPH - Amphastar P | HOLD | 0 @ USD 25.31 | USD 0 | The current share valuation price of AMPH based on adjusted close was USD 25.31. The average price that AMPH shares were previous bought at was USD 25.4428. The current market price is -0.5% lower than average price they were purchased at. The value of the holding in AMPH has increased by USD 1,484 compared to the previous valuation of Amphastar P however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | HOLD | 0 @ USD 11.69 | USD 0 | The current share valuation price of AMRX based on adjusted close was USD 11.69. The average price that AMRX shares were previous bought at was USD 8.7227. The current market price is 34.0% higher than average price they were purchased at. The value of the holding in AMRX has increased by USD 69,354 compared to the previous valuation of Amneal Pharmaceuticals, Inc. Class A Common Stock however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 36 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 36. The average price that ANAB shares were previous bought at was USD 23.8059. The current market price is 51.2% higher than average price they were purchased at. The value of the holding in ANAB has increased by USD 22,534 compared to the previous valuation of AnaptysBio Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| ANIP - ANI Pharmaceuticals Inc | HOLD | 0 @ USD 92.62 | USD 0 | The current share valuation price of ANIP based on adjusted close was USD 92.62. The average price that ANIP shares were previous bought at was USD 71.3477. The current market price is 29.8% higher than average price they were purchased at. The value of the holding in ANIP has fallen by USD 25,774 compared to the previous valuation of ANI Pharmaceuticals Inc |
| APGE - Apogee Therapeutics, Inc. Common Stock | HOLD | 0 @ USD 55.45 | USD 0 | The current share valuation price of APGE based on adjusted close was USD 55.45. The average price that APGE shares were previous bought at was USD 43.2087. The current market price is 28.3% higher than average price they were purchased at. The value of the holding in APGE has increased by USD 45,619 compared to the previous valuation of Apogee Therapeutics, Inc. Common Stock however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| APLS - Apellis Pharmaceuticals Inc | HOLD | 0 @ USD 19.95 | USD 0 | The current share valuation price of APLS based on adjusted close was USD 19.95. The average price that APLS shares were previous bought at was USD 21.0274. The current market price is -5.1% lower than average price they were purchased at. The value of the holding in APLS has fallen by USD 42,644 compared to the previous valuation of Apellis Pharmaceuticals Inc |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 8.64001 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 8.64001. The average price that ARCT shares were previous bought at was USD 14.7591. The current market price is -41.5% lower than average price they were purchased at. The value of the holding in ARCT has fallen by USD 5,287 compared to the previous valuation of Arcturus Therapeutics Holdings Inc |
| ARDX - Ardelyx Inc | HOLD | 0 @ USD 5.95 | USD 0 | The current share valuation price of ARDX based on adjusted close was USD 5.95. The average price that ARDX shares were previous bought at was USD 4.58993. The current market price is 29.6% higher than average price they were purchased at. The value of the holding in ARDX has increased by USD 53,897 compared to the previous valuation of Ardelyx Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| ARGX - argenx NV ADR | HOLD | 0 @ USD 832.35 | USD 0 | The current share valuation price of ARGX based on adjusted close was USD 832.35. The average price that ARGX shares were previous bought at was USD 631.044. The current market price is 31.9% higher than average price they were purchased at. The value of the holding in ARGX has increased by USD 17,177 compared to the previous valuation of argenx NV ADR however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| ARQT - Arcutis Biotherapeutics Inc | HOLD | 0 @ USD 24.38 | USD 0 | The current share valuation price of ARQT based on adjusted close was USD 24.38. The average price that ARQT shares were previous bought at was USD 15.9437. The current market price is 52.9% higher than average price they were purchased at. The value of the holding in ARQT has increased by USD 28,324 compared to the previous valuation of Arcutis Biotherapeutics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 9.56999 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 9.56999. The average price that ARVN shares were previous bought at was USD 8.69691. The current market price is 10.0% higher than average price they were purchased at. The value of the holding in ARVN has increased by USD 1,374 compared to the previous valuation of Arvinas Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| ARWR - Arrowhead Pharmaceuticals Inc | HOLD | 0 @ USD 40.31 | USD 0 | The current share valuation price of ARWR based on adjusted close was USD 40.31. The average price that ARWR shares were previous bought at was USD 20.7027. The current market price is 94.7% higher than average price they were purchased at. The value of the holding in ARWR has increased by USD 219,469 compared to the previous valuation of Arrowhead Pharmaceuticals Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| ASND - Ascendis Pharma AS | HOLD | 0 @ USD 197.75 | USD 0 | The current share valuation price of ASND based on adjusted close was USD 197.75. The average price that ASND shares were previous bought at was USD 176.993. The current market price is 11.7% higher than average price they were purchased at. The value of the holding in ASND has fallen by USD 410,694 compared to the previous valuation of Ascendis Pharma AS |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 14.45 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 14.45. The average price that AUPH shares were previous bought at was USD 8.93429. The current market price is 61.7% higher than average price they were purchased at. The value of the holding in AUPH has increased by USD 15,136 compared to the previous valuation of Aurinia Pharmaceuticals Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| AUTL - Autolus Therapeutics Ltd | HOLD | 0 @ USD 1.385 | USD 0 | The current share valuation price of AUTL based on adjusted close was USD 1.385. The average price that AUTL shares were previous bought at was USD 1.86463. The current market price is -25.7% lower than average price they were purchased at. The value of the holding in AUTL has fallen by USD 3,474 compared to the previous valuation of Autolus Therapeutics Ltd |
| AVDL - Avadel Pharmaceuticals PLC | HOLD | 0 @ USD 18.96 | USD 0 | The current share valuation price of AVDL based on adjusted close was USD 18.96. The average price that AVDL shares were previous bought at was USD 10.6913. The current market price is 77.3% higher than average price they were purchased at. The value of the holding in AVDL has increased by USD 3,722 compared to the previous valuation of Avadel Pharmaceuticals PLC however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| AVIR - Atea Pharmaceuticals Inc | HOLD | 0 @ USD 3.24 | USD 0 | The current share valuation price of AVIR based on adjusted close was USD 3.24. The average price that AVIR shares were previous bought at was USD 3.34458. The current market price is -3.1% lower than average price they were purchased at. The value of the holding in AVIR has increased by USD 1,608 compared to the previous valuation of Atea Pharmaceuticals Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| AVXL - Anavex Life Sciences Corp | HOLD | 0 @ USD 7.31 | USD 0 | The current share valuation price of AVXL based on adjusted close was USD 7.31. The average price that AVXL shares were previous bought at was USD 9.62281. The current market price is -24.0% lower than average price they were purchased at. The value of the holding in AVXL has fallen by USD 8,787 compared to the previous valuation of Anavex Life Sciences Corp |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 135.69 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 135.69. The average price that AXSM shares were previous bought at was USD 113.769. The current market price is 19.3% higher than average price they were purchased at. The value of the holding in AXSM has increased by USD 24,411 compared to the previous valuation of Axsome Therapeutics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| AZN - AstraZeneca PLC | HOLD | 0 @ USD 81.15 | USD 0 | The current share valuation price of AZN based on adjusted close was USD 81.15. The average price that AZN shares were previous bought at was USD 74.3929. The current market price is 9.1% higher than average price they were purchased at. The value of the holding in AZN has fallen by USD 293,838 compared to the previous valuation of AstraZeneca PLC |
| BBIO - BridgeBio Pharma Inc | HOLD | 0 @ USD 62.66 | USD 0 | The current share valuation price of BBIO based on adjusted close was USD 62.66. The average price that BBIO shares were previous bought at was USD 44.0653. The current market price is 42.2% higher than average price they were purchased at. The value of the holding in BBIO has increased by USD 159,399 compared to the previous valuation of BridgeBio Pharma Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.17 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.17. The average price that BCRX shares were previous bought at was USD 8.33473. The current market price is -14.0% lower than average price they were purchased at. The value of the holding in BCRX has increased by USD 54,986 compared to the previous valuation of BioCryst Pharmaceuticals Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| BCYC - Bicycle Therapeutics Ltd | HOLD | 0 @ USD 6.17 | USD 0 | The current share valuation price of BCYC based on adjusted close was USD 6.17. The average price that BCYC shares were previous bought at was USD 8.60581. The current market price is -28.3% lower than average price they were purchased at. The value of the holding in BCYC has fallen by USD 21,210 compared to the previous valuation of Bicycle Therapeutics Ltd |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 23.07 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 23.07. The average price that BEAM shares were previous bought at was USD 20.5607. The current market price is 12.2% higher than average price they were purchased at. The value of the holding in BEAM has increased by USD 21,309 compared to the previous valuation of Beam Therapeutics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 153.43 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 153.43. The average price that BIIB shares were previous bought at was USD 137.382. The current market price is 11.7% higher than average price they were purchased at. The value of the holding in BIIB has increased by USD 387,705 compared to the previous valuation of Biogen Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| BMEA - Biomea Fusion Inc | HOLD | 0 @ USD 1.34 | USD 0 | The current share valuation price of BMEA based on adjusted close was USD 1.34. The average price that BMEA shares were previous bought at was USD 1.82435. The current market price is -26.5% lower than average price they were purchased at. The value of the holding in BMEA has increased by USD 3,546 compared to the previous valuation of Biomea Fusion Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| BMRN - Biomarin Pharmaceutical Inc | HOLD | 0 @ USD 52.8 | USD 0 | The current share valuation price of BMRN based on adjusted close was USD 52.8. The average price that BMRN shares were previous bought at was USD 58.3808. The current market price is -9.6% lower than average price they were purchased at. The value of the holding in BMRN has increased by USD 34,584 compared to the previous valuation of Biomarin Pharmaceutical Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| BNTX - BioNTech SE | HOLD | 0 @ USD 103.43 | USD 0 | The current share valuation price of BNTX based on adjusted close was USD 103.43. The average price that BNTX shares were previous bought at was USD 105.305. The current market price is -1.8% lower than average price they were purchased at. The value of the holding in BNTX has fallen by USD 90,604 compared to the previous valuation of BioNTech SE |
| CGEM - Cullinan Oncology LLC | HOLD | 0 @ USD 7.30999 | USD 0 | The current share valuation price of CGEM based on adjusted close was USD 7.30999. The average price that CGEM shares were previous bought at was USD 7.86505. The current market price is -7.1% lower than average price they were purchased at. The value of the holding in CGEM has fallen by USD 3,519 compared to the previous valuation of Cullinan Oncology LLC |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 37.96 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 37.96. The average price that CGON shares were previous bought at was USD 29.6278. The current market price is 28.1% higher than average price they were purchased at. The value of the holding in CGON has fallen by USD 54,909 compared to the previous valuation of CG Oncology, Inc. Common stock |
| CNTA - Centessa Pharmaceuticals PLC ADR | HOLD | 0 @ USD 22.52 | USD 0 | The current share valuation price of CNTA based on adjusted close was USD 22.52. The average price that CNTA shares were previous bought at was USD 16.3074. The current market price is 38.1% higher than average price they were purchased at. The value of the holding in CNTA has fallen by USD 74,709 compared to the previous valuation of Centessa Pharmaceuticals PLC ADR |
| COGT - Cogent Biosciences Inc | HOLD | 0 @ USD 14.42 | USD 0 | The current share valuation price of COGT based on adjusted close was USD 14.42. The average price that COGT shares were previous bought at was USD 10.6212. The current market price is 35.8% higher than average price they were purchased at. The value of the holding in COGT has increased by USD 25,858 compared to the previous valuation of Cogent Biosciences Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| COLL - Collegium Pharmaceutical Inc | HOLD | 0 @ USD 35.85 | USD 0 | The current share valuation price of COLL based on adjusted close was USD 35.85. The average price that COLL shares were previous bought at was USD 31.3238. The current market price is 14.4% higher than average price they were purchased at. The value of the holding in COLL has increased by USD 1,811 compared to the previous valuation of Collegium Pharmaceutical Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| CRNX - Crinetics Pharmaceuticals Inc | HOLD | 0 @ USD 42.53 | USD 0 | The current share valuation price of CRNX based on adjusted close was USD 42.53. The average price that CRNX shares were previous bought at was USD 34.6699. The current market price is 22.7% higher than average price they were purchased at. The value of the holding in CRNX has increased by USD 1,218 compared to the previous valuation of Crinetics Pharmaceuticals Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| CRSP - Crispr Therapeutics AG | HOLD | 0 @ USD 56.99 | USD 0 | The current share valuation price of CRSP based on adjusted close was USD 56.99. The average price that CRSP shares were previous bought at was USD 52.493. The current market price is 8.6% higher than average price they were purchased at. The value of the holding in CRSP has increased by USD 33,934 compared to the previous valuation of Crispr Therapeutics AG however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| CVAC - CureVac NV | HOLD | 0 @ USD 5.27 | USD 0 | The current share valuation price of CVAC based on adjusted close was USD 5.27. The average price that CVAC shares were previous bought at was USD 4.83111. The current market price is 9.1% higher than average price they were purchased at. The value of the holding in CVAC has fallen by USD 4,316 compared to the previous valuation of CureVac NV |
| CYTK - Cytokinetics Inc | HOLD | 0 @ USD 59.19 | USD 0 | The current share valuation price of CYTK based on adjusted close was USD 59.19. The average price that CYTK shares were previous bought at was USD 42.0909. The current market price is 40.6% higher than average price they were purchased at. The value of the holding in CYTK has fallen by USD 33,098 compared to the previous valuation of Cytokinetics Inc |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 9.14 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 9.14. The average price that DAWN shares were previous bought at was USD 7.37094. The current market price is 24.0% higher than average price they were purchased at. The value of the holding in DAWN has increased by USD 119,521 compared to the previous valuation of Day One Biopharmaceuticals Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| DNLI - Denali Therapeutics Inc | HOLD | 0 @ USD 14.89 | USD 0 | The current share valuation price of DNLI based on adjusted close was USD 14.89. The average price that DNLI shares were previous bought at was USD 15.0851. The current market price is -1.3% lower than average price they were purchased at. The value of the holding in DNLI has fallen by USD 2,801 compared to the previous valuation of Denali Therapeutics Inc |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 10.3 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 10.3. The average price that DVAX shares were previous bought at was USD 10.4605. The current market price is -1.5% lower than average price they were purchased at. The value of the holding in DVAX has increased by USD 18,734 compared to the previous valuation of Dynavax Technologies Corporation however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| DYN - Dyne Therapeutics Inc | HOLD | 0 @ USD 20.9 | USD 0 | The current share valuation price of DYN based on adjusted close was USD 20.9. The average price that DYN shares were previous bought at was USD 12.7136. The current market price is 64.4% higher than average price they were purchased at. The value of the holding in DYN has fallen by USD 57,234 compared to the previous valuation of Dyne Therapeutics Inc |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | HOLD | 0 @ USD 20.9 | USD 0 | The current share valuation price of DYN based on adjusted close was USD 20.9. The average price that DYN shares were previous bought at was USD 12.7136. The current market price is 64.4% higher than average price they were purchased at. The value of the holding in DYN has fallen by USD 57,234 compared to the previous valuation of DYNAGREEN EN.PR.GR.H YC 1 |
| EDIT - Editas Medicine Inc | HOLD | 0 @ USD 2.78 | USD 0 | The current share valuation price of EDIT based on adjusted close was USD 2.78. The average price that EDIT shares were previous bought at was USD 2.74658. The current market price is 1.2% higher than average price they were purchased at. USD 0 compared to the previous valuation of Editas Medicine Inc |
| ELVN - Enliven Therapeutics Inc. | HOLD | 0 @ USD 18.5 | USD 0 | The current share valuation price of ELVN based on adjusted close was USD 18.5. The average price that ELVN shares were previous bought at was USD 20.3815. The current market price is -9.2% lower than average price they were purchased at. The value of the holding in ELVN has fallen by USD 19,281 compared to the previous valuation of Enliven Therapeutics Inc. |
| EOLS - Evolus Inc | HOLD | 0 @ USD 6.81 | USD 0 | The current share valuation price of EOLS based on adjusted close was USD 6.81. The average price that EOLS shares were previous bought at was USD 9.25019. The current market price is -26.4% lower than average price they were purchased at. The value of the holding in EOLS has increased by USD 17,922 compared to the previous valuation of Evolus Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| ERAS - Erasca Inc | HOLD | 0 @ USD 2.2 | USD 0 | The current share valuation price of ERAS based on adjusted close was USD 2.2. The average price that ERAS shares were previous bought at was USD 1.62905. The current market price is 35.0% higher than average price they were purchased at. The value of the holding in ERAS has fallen by USD 21,326 compared to the previous valuation of Erasca Inc |
| EWTX - Edgewise Therapeutics Inc | HOLD | 0 @ USD 17.37 | USD 0 | The current share valuation price of EWTX based on adjusted close was USD 17.37. The average price that EWTX shares were previous bought at was USD 15.7431. The current market price is 10.3% higher than average price they were purchased at. The value of the holding in EWTX has increased by USD 3,028 compared to the previous valuation of Edgewise Therapeutics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| EXEL - Exelixis Inc | HOLD | 0 @ USD 40.37 | USD 0 | The current share valuation price of EXEL based on adjusted close was USD 40.37. The average price that EXEL shares were previous bought at was USD 40.8999. The current market price is -1.3% lower than average price they were purchased at. The value of the holding in EXEL has increased by USD 427,759 compared to the previous valuation of Exelixis Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| EYPT - Eyepoint Pharmaceuticals Inc | HOLD | 0 @ USD 11.015 | USD 0 | The current share valuation price of EYPT based on adjusted close was USD 11.015. The average price that EYPT shares were previous bought at was USD 8.68404. The current market price is 26.8% higher than average price they were purchased at. The value of the holding in EYPT has fallen by USD 60,564 compared to the previous valuation of Eyepoint Pharmaceuticals Inc |
| FATE - Fate Therapeutics Inc | HOLD | 0 @ USD 1.09 | USD 0 | The current share valuation price of FATE based on adjusted close was USD 1.09. The average price that FATE shares were previous bought at was USD 1.1922. The current market price is -8.6% lower than average price they were purchased at. The value of the holding in FATE has fallen by USD 6,960 compared to the previous valuation of Fate Therapeutics Inc |
| FDMT - 4D Molecular Therapeutics Inc | HOLD | 0 @ USD 10.51 | USD 0 | The current share valuation price of FDMT based on adjusted close was USD 10.51. The average price that FDMT shares were previous bought at was USD 6.10392. The current market price is 72.2% higher than average price they were purchased at. The value of the holding in FDMT has fallen by USD 7,677 compared to the previous valuation of 4D Molecular Therapeutics Inc |
| FOLD - Amicus Therapeutics Inc | HOLD | 0 @ USD 9.19 | USD 0 | The current share valuation price of FOLD based on adjusted close was USD 9.19. The average price that FOLD shares were previous bought at was USD 7.29317. The current market price is 26.0% higher than average price they were purchased at. The value of the holding in FOLD has increased by USD 39,359 compared to the previous valuation of Amicus Therapeutics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 11.95 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 11.95. The average price that FTRE shares were previous bought at was USD 6.48679. The current market price is 84.2% higher than average price they were purchased at. The value of the holding in FTRE has increased by USD 130,581 compared to the previous valuation of Fortrea Holdings Inc. however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| GERN - Geron Corporation | HOLD | 0 @ USD 1.09 | USD 0 | The current share valuation price of GERN based on adjusted close was USD 1.09. The average price that GERN shares were previous bought at was USD 1.51743. The current market price is -28.2% lower than average price they were purchased at. The value of the holding in GERN has fallen by USD 24,218 compared to the previous valuation of Geron Corporation |
| GH - Guardant Health Inc | HOLD | 0 @ USD 95.05 | USD 0 | The current share valuation price of GH based on adjusted close was USD 95.05. The average price that GH shares were previous bought at was USD 53.7878. The current market price is 76.7% higher than average price they were purchased at. The value of the holding in GH has fallen by USD 249,502 compared to the previous valuation of Guardant Health Inc |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 122.58 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 122.58. The average price that GILD shares were previous bought at was USD 112.464. The current market price is 9.0% higher than average price they were purchased at. The value of the holding in GILD has fallen by USD 198,376 compared to the previous valuation of Guild Esports Plc |
| GLPG - Galapagos NV ADR | HOLD | 0 @ USD 29.89 | USD 0 | The current share valuation price of GLPG based on adjusted close was USD 29.89. The average price that GLPG shares were previous bought at was USD 29.0975. The current market price is 2.7% higher than average price they were purchased at. The value of the holding in GLPG has fallen by USD 5,518 compared to the previous valuation of Galapagos NV ADR |
| GLPG - Galapagos N.V. | HOLD | 0 @ USD 29.89 | USD 0 | The current share valuation price of GLPG based on adjusted close was USD 29.89. The average price that GLPG shares were previous bought at was USD 29.0975. The current market price is 2.7% higher than average price they were purchased at. The value of the holding in GLPG has fallen by USD 5,518 compared to the previous valuation of Galapagos N.V. |
| GMAB - Genmab AS | HOLD | 0 @ USD 29.19 | USD 0 | The current share valuation price of GMAB based on adjusted close was USD 29.19. The average price that GMAB shares were previous bought at was USD 23.2283. The current market price is 25.7% higher than average price they were purchased at. The value of the holding in GMAB has increased by USD 11,511 compared to the previous valuation of Genmab AS however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | HOLD | 0 @ USD 32.21 | USD 0 | The current share valuation price of GPCR based on adjusted close was USD 32.21. The average price that GPCR shares were previous bought at was USD 22.6606. The current market price is 42.1% higher than average price they were purchased at. The value of the holding in GPCR has fallen by USD 68,472 compared to the previous valuation of Structure Therapeutics Inc. American Depositary Shares |
| GRAL - GRAIL, LLC | HOLD | 0 @ USD 84.64 | USD 0 | The current share valuation price of GRAL based on adjusted close was USD 84.64. The average price that GRAL shares were previous bought at was USD 51.4862. The current market price is 64.4% higher than average price they were purchased at. The value of the holding in GRAL has increased by USD 92,548 compared to the previous valuation of GRAIL, LLC however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| GRFS - Grifols SA ADR | HOLD | 0 @ USD 8.63 | USD 0 | The current share valuation price of GRFS based on adjusted close was USD 8.63. The average price that GRFS shares were previous bought at was USD 9.46772. The current market price is -8.8% lower than average price they were purchased at. The value of the holding in GRFS has fallen by USD 46,004 compared to the previous valuation of Grifols SA ADR |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 68.3 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 68.3. The average price that HALO shares were previous bought at was USD 59.2753. The current market price is 15.2% higher than average price they were purchased at. The value of the holding in HALO has increased by USD 18,810 compared to the previous valuation of Halozyme Therapeutics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| HCM - HUTCHMED China Ltd | HOLD | 0 @ USD 15.57 | USD 0 | The current share valuation price of HCM based on adjusted close was USD 15.57. The average price that HCM shares were previous bought at was USD 15.5106. The current market price is 0.4% higher than average price they were purchased at. The value of the holding in HCM has increased by USD 2,644 compared to the previous valuation of HUTCHMED China Ltd however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| HCM - Hitachi Construction Machinery Co. Ltd | HOLD | 0 @ USD 15.57 | USD 0 | The current share valuation price of HCM based on adjusted close was USD 15.57. The average price that HCM shares were previous bought at was USD 15.5106. The current market price is 0.4% higher than average price they were purchased at. The value of the holding in HCM has increased by USD 2,644 compared to the previous valuation of Hitachi Construction Machinery Co. Ltd however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 31.35 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 31.35. The average price that HRMY shares were previous bought at was USD 31.8317. The current market price is -1.5% lower than average price they were purchased at. The value of the holding in HRMY has increased by USD 23,144 compared to the previous valuation of Harmony Biosciences Holdings however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| HROW - Harrow Health Inc | HOLD | 0 @ USD 35.42 | USD 0 | The current share valuation price of HROW based on adjusted close was USD 35.42. The average price that HROW shares were previous bought at was USD 33.2308. The current market price is 6.6% higher than average price they were purchased at. The value of the holding in HROW has increased by USD 2,598 compared to the previous valuation of Harrow Health Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| HUMA - Humacyte Inc | HOLD | 0 @ USD 1.45 | USD 0 | The current share valuation price of HUMA based on adjusted close was USD 1.45. The average price that HUMA shares were previous bought at was USD 2.23657. The current market price is -35.2% lower than average price they were purchased at. The value of the holding in HUMA has fallen by USD 1,039 compared to the previous valuation of Humacyte Inc |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.15 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.15. The average price that IBRX shares were previous bought at was USD 2.77213. The current market price is -22.4% lower than average price they were purchased at. The value of the holding in IBRX has increased by USD 42,855 compared to the previous valuation of Immunitybio Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 29.66 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 29.66. The average price that IDYA shares were previous bought at was USD 23.1053. The current market price is 28.4% higher than average price they were purchased at. The value of the holding in IDYA has fallen by USD 46,824 compared to the previous valuation of Ideaya Biosciences Inc |
| ILMN - Illumina Inc | HOLD | 0 @ USD 122.44 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 122.44. The average price that ILMN shares were previous bought at was USD 96.6282. The current market price is 26.7% higher than average price they were purchased at. The value of the holding in ILMN has increased by USD 551,722 compared to the previous valuation of Illumina Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| IMCR - Immunocore Holdings Ltd | HOLD | 0 @ USD 30.8 | USD 0 | The current share valuation price of IMCR based on adjusted close was USD 30.8. The average price that IMCR shares were previous bought at was USD 32.6522. The current market price is -5.7% lower than average price they were purchased at. The value of the holding in IMCR has fallen by USD 29,164 compared to the previous valuation of Immunocore Holdings Ltd |
| IMVT - Immunovant Inc | HOLD | 0 @ USD 23.6 | USD 0 | The current share valuation price of IMVT based on adjusted close was USD 23.6. The average price that IMVT shares were previous bought at was USD 17.8723. The current market price is 32.0% higher than average price they were purchased at. The value of the holding in IMVT has fallen by USD 66,871 compared to the previous valuation of Immunovant Inc |
| INCY - Incyte Corporation | HOLD | 0 @ USD 105.7 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 105.7. The average price that INCY shares were previous bought at was USD 73.2301. The current market price is 44.3% higher than average price they were purchased at. The value of the holding in INCY has increased by USD 350,344 compared to the previous valuation of Incyte Corporation however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| INSM - Insmed Inc | HOLD | 0 @ USD 186.88 | USD 0 | The current share valuation price of INSM based on adjusted close was USD 186.88. The average price that INSM shares were previous bought at was USD 117.875. The current market price is 58.5% higher than average price they were purchased at. The value of the holding in INSM has increased by USD 560,152 compared to the previous valuation of Insmed Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| INVA - Innoviva Inc | HOLD | 0 @ USD 18.23 | USD 0 | The current share valuation price of INVA based on adjusted close was USD 18.23. The average price that INVA shares were previous bought at was USD 18.8301. The current market price is -3.2% lower than average price they were purchased at. The value of the holding in INVA has increased by USD 3,202 compared to the previous valuation of Innoviva Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| IONS - Ionis Pharmaceuticals Inc | HOLD | 0 @ USD 74.68 | USD 0 | The current share valuation price of IONS based on adjusted close was USD 74.68. The average price that IONS shares were previous bought at was USD 47.4239. The current market price is 57.5% higher than average price they were purchased at. The value of the holding in IONS has increased by USD 185,477 compared to the previous valuation of Ionis Pharmaceuticals Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 1.81 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 1.81. The average price that IOVA shares were previous bought at was USD 2.43787. The current market price is -25.8% lower than average price they were purchased at. The value of the holding in IOVA has fallen by USD 2,267 compared to the previous valuation of Iovance Biotherapeutics Inc |
| IRON - Ironveld Plc | HOLD | 0 @ USD 88.31 | USD 0 | The current share valuation price of IRON based on adjusted close was USD 88.31. The average price that IRON shares were previous bought at was USD 58.2514. The current market price is 51.6% higher than average price they were purchased at. The value of the holding in IRON has increased by USD 50,841 compared to the previous valuation of Ironveld Plc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| IRWD - Ironwood Pharmaceuticals Inc | HOLD | 0 @ USD 2.06 | USD 0 | The current share valuation price of IRWD based on adjusted close was USD 2.06. The average price that IRWD shares were previous bought at was USD 1.11153. The current market price is 85.3% higher than average price they were purchased at. The value of the holding in IRWD has increased by USD 18,557 compared to the previous valuation of Ironwood Pharmaceuticals Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| JANX - Janux Therapeutics Inc | HOLD | 0 @ USD 27.54 | USD 0 | The current share valuation price of JANX based on adjusted close was USD 27.54. The average price that JANX shares were previous bought at was USD 27.66. The current market price is -0.4% lower than average price they were purchased at. The value of the holding in JANX has increased by USD 20,337 compared to the previous valuation of Janux Therapeutics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| JAZZ - Jazz Pharmaceuticals PLC | HOLD | 0 @ USD 137.22 | USD 0 | The current share valuation price of JAZZ based on adjusted close was USD 137.22. The average price that JAZZ shares were previous bought at was USD 121.217. The current market price is 13.2% higher than average price they were purchased at. The value of the holding in JAZZ has fallen by USD 23,414 compared to the previous valuation of Jazz Pharmaceuticals PLC |
| KALV - Kalvista Pharmaceuticals Inc | HOLD | 0 @ USD 10.99 | USD 0 | The current share valuation price of KALV based on adjusted close was USD 10.99. The average price that KALV shares were previous bought at was USD 12.3583. The current market price is -11.1% lower than average price they were purchased at. The value of the holding in KALV has increased by USD 7,218 compared to the previous valuation of Kalvista Pharmaceuticals Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 39.14 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 39.14. The average price that KNSA shares were previous bought at was USD 29.4305. The current market price is 33.0% higher than average price they were purchased at. The value of the holding in KNSA has increased by USD 16,893 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| KROS - Keros Therapeutics Inc | HOLD | 0 @ USD 15.65 | USD 0 | The current share valuation price of KROS based on adjusted close was USD 15.65. The average price that KROS shares were previous bought at was USD 13.651. The current market price is 14.6% higher than average price they were purchased at. The value of the holding in KROS has increased by USD 2,556 compared to the previous valuation of Keros Therapeutics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| KRYS - Krystal Biotech Inc | HOLD | 0 @ USD 199.88 | USD 0 | The current share valuation price of KRYS based on adjusted close was USD 199.88. The average price that KRYS shares were previous bought at was USD 159.295. The current market price is 25.5% higher than average price they were purchased at. The value of the holding in KRYS has fallen by USD 63,074 compared to the previous valuation of Krystal Biotech Inc |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 9.93999 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 9.93999. The average price that KURA shares were previous bought at was USD 7.15552. The current market price is 38.9% higher than average price they were purchased at. The value of the holding in KURA has fallen by USD 1,156 compared to the previous valuation of Kura Oncology Inc |
| KYMR - Kymera Therapeutics Inc | HOLD | 0 @ USD 59.89 | USD 0 | The current share valuation price of KYMR based on adjusted close was USD 59.89. The average price that KYMR shares were previous bought at was USD 46.0961. The current market price is 29.9% higher than average price they were purchased at. The value of the holding in KYMR has fallen by USD 925 compared to the previous valuation of Kymera Therapeutics Inc |
| LEGN - Legend Biotech Corp | HOLD | 0 @ USD 32.01 | USD 0 | The current share valuation price of LEGN based on adjusted close was USD 32.01. The average price that LEGN shares were previous bought at was USD 34.8994. The current market price is -8.3% lower than average price they were purchased at. The value of the holding in LEGN has fallen by USD 2,170 compared to the previous valuation of Legend Biotech Corp |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 190.38 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 190.38. The average price that LGND shares were previous bought at was USD 130.735. The current market price is 45.6% higher than average price they were purchased at. The value of the holding in LGND has increased by USD 11,806 compared to the previous valuation of Ligand Pharmaceuticals Incorporated however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| LXRX - Lexicon Pharmaceuticals Inc | HOLD | 0 @ USD 1.38 | USD 0 | The current share valuation price of LXRX based on adjusted close was USD 1.38. The average price that LXRX shares were previous bought at was USD 1.03389. The current market price is 33.5% higher than average price they were purchased at. The value of the holding in LXRX has increased by USD 12,072 compared to the previous valuation of Lexicon Pharmaceuticals Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| LYEL - Lyell Immunopharma Inc | HOLD | 0 @ USD 16.54 | USD 0 | The current share valuation price of LYEL based on adjusted close was USD 16.54. The average price that LYEL shares were previous bought at was USD 6.286. The current market price is 163.1% higher than average price they were purchased at. The value of the holding in LYEL has increased by USD 7,251 compared to the previous valuation of Lyell Immunopharma Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| MDGL - Madrigal Pharmaceuticals Inc | HOLD | 0 @ USD 475.87 | USD 0 | The current share valuation price of MDGL based on adjusted close was USD 475.87. The average price that MDGL shares were previous bought at was USD 342.071. The current market price is 39.1% higher than average price they were purchased at. The value of the holding in MDGL has increased by USD 447,838 compared to the previous valuation of Madrigal Pharmaceuticals Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 598.81 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 598.81. The average price that MEDP shares were previous bought at was USD 386.096. The current market price is 55.1% higher than average price they were purchased at. The value of the holding in MEDP has increased by USD 77,610 compared to the previous valuation of Medpace Holdings Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| MGNX - MacroGenics Inc | HOLD | 0 @ USD 1.43999 | USD 0 | The current share valuation price of MGNX based on adjusted close was USD 1.43999. The average price that MGNX shares were previous bought at was USD 1.58108. The current market price is -8.9% lower than average price they were purchased at. The value of the holding in MGNX has fallen by USD 395 compared to the previous valuation of MacroGenics Inc |
| MGTX - MeiraGTx Holdings PLC | HOLD | 0 @ USD 8.58 | USD 0 | The current share valuation price of MGTX based on adjusted close was USD 8.58. The average price that MGTX shares were previous bought at was USD 7.19461. The current market price is 19.3% higher than average price they were purchased at. The value of the holding in MGTX has increased by USD 1,029 compared to the previous valuation of MeiraGTx Holdings PLC however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| MIRM - Mirum Pharmaceuticals Inc | HOLD | 0 @ USD 70.09 | USD 0 | The current share valuation price of MIRM based on adjusted close was USD 70.09. The average price that MIRM shares were previous bought at was USD 55.0024. The current market price is 27.4% higher than average price they were purchased at. The value of the holding in MIRM has fallen by USD 28,644 compared to the previous valuation of Mirum Pharmaceuticals Inc |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | HOLD | 0 @ USD 39.65 | USD 0 | The current share valuation price of MLYS based on adjusted close was USD 39.65. The average price that MLYS shares were previous bought at was USD 19.2083. The current market price is 106.4% higher than average price they were purchased at. The value of the holding in MLYS has fallen by USD 6,768 compared to the previous valuation of Mineralys Therapeutics, Inc. Common Stock |
| MNKD - MannKind Corp | HOLD | 0 @ USD 6.06 | USD 0 | The current share valuation price of MNKD based on adjusted close was USD 6.06. The average price that MNKD shares were previous bought at was USD 4.70442. The current market price is 28.8% higher than average price they were purchased at. The value of the holding in MNKD has increased by USD 113,701 compared to the previous valuation of MannKind Corp however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| MNMD - Mind Medicine Inc | HOLD | 0 @ USD 11.53 | USD 0 | The current share valuation price of MNMD based on adjusted close was USD 11.53. The average price that MNMD shares were previous bought at was USD 8.49523. The current market price is 35.7% higher than average price they were purchased at. The value of the holding in MNMD has fallen by USD 23,275 compared to the previous valuation of Mind Medicine Inc |
| MRNA - Moderna Inc | HOLD | 0 @ USD 23.56 | USD 0 | The current share valuation price of MRNA based on adjusted close was USD 23.56. The average price that MRNA shares were previous bought at was USD 29.378. The current market price is -19.8% lower than average price they were purchased at. The value of the holding in MRNA has fallen by USD 47,557 compared to the previous valuation of Moderna Inc |
| MRSN - Mersana Therapeutics Inc | HOLD | 0 @ USD 8.45988 | USD 0 | The current share valuation price of MRSN based on adjusted close was USD 8.45988. The average price that MRSN shares were previous bought at was USD 0.526763. The current market price is 1,506.0% higher than average price they were purchased at. The value of the holding in MRSN has increased by USD 904 compared to the previous valuation of Mersana Therapeutics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| MRUS - Merus BV | HOLD | 0 @ USD 95.18 | USD 0 | The current share valuation price of MRUS based on adjusted close was USD 95.18. The average price that MRUS shares were previous bought at was USD 63.0714. The current market price is 50.9% higher than average price they were purchased at. The value of the holding in MRUS has increased by USD 6,828 compared to the previous valuation of Merus BV however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 2.87 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 2.87. The average price that MRVI shares were previous bought at was USD 2.68965. The current market price is 6.7% higher than average price they were purchased at. USD 0 compared to the previous valuation of Maravai Lifesciences Holdings Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| MXCT - MaxCyte Inc | HOLD | 0 @ USD 1.67 | USD 0 | The current share valuation price of MXCT based on adjusted close was USD 1.67. The average price that MXCT shares were previous bought at was USD 2.20026. The current market price is -24.1% lower than average price they were purchased at. The value of the holding in MXCT has increased by USD 4,103 compared to the previous valuation of MaxCyte Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 153.75 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 153.75. The average price that NBIX shares were previous bought at was USD 129.315. The current market price is 18.9% higher than average price they were purchased at. The value of the holding in NBIX has increased by USD 676,411 compared to the previous valuation of Neurocrine Biosciences Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| NRIX - Nurix Therapeutics Inc | HOLD | 0 @ USD 12.455 | USD 0 | The current share valuation price of NRIX based on adjusted close was USD 12.455. The average price that NRIX shares were previous bought at was USD 12.0495. The current market price is 3.4% higher than average price they were purchased at. The value of the holding in NRIX has increased by USD 10,016 compared to the previous valuation of Nurix Therapeutics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| NTLA - Intellia Therapeutics Inc | HOLD | 0 @ USD 13.57 | USD 0 | The current share valuation price of NTLA based on adjusted close was USD 13.57. The average price that NTLA shares were previous bought at was USD 12.5347. The current market price is 8.3% higher than average price they were purchased at. The value of the holding in NTLA has increased by USD 95,104 compared to the previous valuation of Intellia Therapeutics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| NUVL - Nuvalent Inc | HOLD | 0 @ USD 92.09 | USD 0 | The current share valuation price of NUVL based on adjusted close was USD 92.09. The average price that NUVL shares were previous bought at was USD 81.5546. The current market price is 12.9% higher than average price they were purchased at. The value of the holding in NUVL has increased by USD 45,951 compared to the previous valuation of Nuvalent Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| NVAX - Novavax Inc | HOLD | 0 @ USD 7.69 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 7.69. The average price that NVAX shares were previous bought at was USD 7.38325. The current market price is 4.2% higher than average price they were purchased at. The value of the holding in NVAX has increased by USD 18,679 compared to the previous valuation of Novavax Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 7.69 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 7.69. The average price that NVAX shares were previous bought at was USD 7.38325. The current market price is 4.2% higher than average price they were purchased at. The value of the holding in NVAX has increased by USD 18,679 compared to the previous valuation of Hana Microelectronics Public Company Limited however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 11.61 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 11.61. The average price that NVCR shares were previous bought at was USD 16.8363. The current market price is -31.0% lower than average price they were purchased at. The value of the holding in NVCR has fallen by USD 27,852 compared to the previous valuation of Novocure Ltd |
| OABI - OmniAb Inc. | HOLD | 0 @ USD 1.42501 | USD 0 | The current share valuation price of OABI based on adjusted close was USD 1.42501. The average price that OABI shares were previous bought at was USD 1.92855. The current market price is -26.1% lower than average price they were purchased at. The value of the holding in OABI has fallen by USD 4,337 compared to the previous valuation of OmniAb Inc. |
| OCUL - Ocular Therapeutix Inc | HOLD | 0 @ USD 10.81 | USD 0 | The current share valuation price of OCUL based on adjusted close was USD 10.81. The average price that OCUL shares were previous bought at was USD 9.9428. The current market price is 8.7% higher than average price they were purchased at. The value of the holding in OCUL has fallen by USD 9,998 compared to the previous valuation of Ocular Therapeutix Inc |
| OKUR - OKUR | HOLD | 0 @ USD 3 | USD 0 | The current share valuation price of OKUR based on adjusted close was USD 3. The average price that OKUR shares were previous bought at was USD 6.12924. The current market price is -51.1% lower than average price they were purchased at. The value of the holding in OKUR has fallen by USD 777 compared to the previous valuation of OKUR |
| OLMA - Olema Pharmaceuticals Inc | HOLD | 0 @ USD 7.95 | USD 0 | The current share valuation price of OLMA based on adjusted close was USD 7.95. The average price that OLMA shares were previous bought at was USD 5.46621. The current market price is 45.4% higher than average price they were purchased at. The value of the holding in OLMA has fallen by USD 10,765 compared to the previous valuation of Olema Pharmaceuticals Inc |
| ORIC - Oric Pharmaceuticals Inc | HOLD | 0 @ USD 12.38 | USD 0 | The current share valuation price of ORIC based on adjusted close was USD 12.38. The average price that ORIC shares were previous bought at was USD 10.4579. The current market price is 18.4% higher than average price they were purchased at. The value of the holding in ORIC has increased by USD 4,961 compared to the previous valuation of Oric Pharmaceuticals Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 1.915 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 1.915. The average price that PACB shares were previous bought at was USD 1.53911. The current market price is 24.4% higher than average price they were purchased at. The value of the holding in PACB has fallen by USD 17,209 compared to the previous valuation of Pacific Biosciences of California |
| PAHC - Phibro Animal Health Corporation | HOLD | 0 @ USD 41.15 | USD 0 | The current share valuation price of PAHC based on adjusted close was USD 41.15. The average price that PAHC shares were previous bought at was USD 28.2482. The current market price is 45.7% higher than average price they were purchased at. The value of the holding in PAHC has fallen by USD 12,342 compared to the previous valuation of Phibro Animal Health Corporation |
| PCRX - Pacira BioSciences, Inc. | HOLD | 0 @ USD 21.85 | USD 0 | The current share valuation price of PCRX based on adjusted close was USD 21.85. The average price that PCRX shares were previous bought at was USD 23.7962. The current market price is -8.2% lower than average price they were purchased at. The value of the holding in PCRX has fallen by USD 16,930 compared to the previous valuation of Pacira BioSciences, Inc. |
| PCVX - Vaxcyte Inc | HOLD | 0 @ USD 40.32 | USD 0 | The current share valuation price of PCVX based on adjusted close was USD 40.32. The average price that PCVX shares were previous bought at was USD 44.3939. The current market price is -9.2% lower than average price they were purchased at. The value of the holding in PCVX has fallen by USD 86,204 compared to the previous valuation of Vaxcyte Inc |
| PGEN - Precigen Inc | HOLD | 0 @ USD 3.99 | USD 0 | The current share valuation price of PGEN based on adjusted close was USD 3.99. The average price that PGEN shares were previous bought at was USD 2.21859. The current market price is 79.8% higher than average price they were purchased at. The value of the holding in PGEN has increased by USD 21,417 compared to the previous valuation of Precigen Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| PHAT - Phathom Pharmaceuticals Inc | HOLD | 0 @ USD 13.28 | USD 0 | The current share valuation price of PHAT based on adjusted close was USD 13.28. The average price that PHAT shares were previous bought at was USD 8.82872. The current market price is 50.4% higher than average price they were purchased at. The value of the holding in PHAT has fallen by USD 9,711 compared to the previous valuation of Phathom Pharmaceuticals Inc |
| PLRX - Pliant Therapeutics Inc | HOLD | 0 @ USD 1.63999 | USD 0 | The current share valuation price of PLRX based on adjusted close was USD 1.63999. The average price that PLRX shares were previous bought at was USD 1.49082. The current market price is 10.0% higher than average price they were purchased at. The value of the holding in PLRX has increased by USD 1,116 compared to the previous valuation of Pliant Therapeutics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 164.64 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 164.64. The average price that PRAX shares were previous bought at was USD 59.5523. The current market price is 176.5% higher than average price they were purchased at. The value of the holding in PRAX has fallen by USD 96,682 compared to the previous valuation of Praxis Precision Medicines Inc |
| PRME - Prime Medicine, Inc. Common Stock | HOLD | 0 @ USD 4.4 | USD 0 | The current share valuation price of PRME based on adjusted close was USD 4.4. The average price that PRME shares were previous bought at was USD 4.56417. The current market price is -3.6% lower than average price they were purchased at. The value of the holding in PRME has increased by USD 11,169 compared to the previous valuation of Prime Medicine, Inc. Common Stock however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| PRTA - Prothena Corporation plc | HOLD | 0 @ USD 10.27 | USD 0 | The current share valuation price of PRTA based on adjusted close was USD 10.27. The average price that PRTA shares were previous bought at was USD 8.94425. The current market price is 14.8% higher than average price they were purchased at. The value of the holding in PRTA has increased by USD 351 compared to the previous valuation of Prothena Corporation plc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 71.77 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 71.77. The average price that PTCT shares were previous bought at was USD 54.2091. The current market price is 32.4% higher than average price they were purchased at. The value of the holding in PTCT has increased by USD 207,474 compared to the previous valuation of PTC Therapeutics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| PTGX - Protagonist Therapeutics Inc | HOLD | 0 @ USD 77.88 | USD 0 | The current share valuation price of PTGX based on adjusted close was USD 77.88. The average price that PTGX shares were previous bought at was USD 55.7643. The current market price is 39.7% higher than average price they were purchased at. The value of the holding in PTGX has increased by USD 55,504 compared to the previous valuation of Protagonist Therapeutics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| QURE - Uniqure NV | HOLD | 0 @ USD 26.06 | USD 0 | The current share valuation price of QURE based on adjusted close was USD 26.06. The average price that QURE shares were previous bought at was USD 22.8064. The current market price is 14.3% higher than average price they were purchased at. The value of the holding in QURE has fallen by USD 154,605 compared to the previous valuation of Uniqure NV |
| RARE - Ultragenyx | HOLD | 0 @ USD 31.87 | USD 0 | The current share valuation price of RARE based on adjusted close was USD 31.87. The average price that RARE shares were previous bought at was USD 36.4002. The current market price is -12.4% lower than average price they were purchased at. The value of the holding in RARE has fallen by USD 36,966 compared to the previous valuation of Ultragenyx |
| RARE - WISETFWTMRARETFP | HOLD | 0 @ USD 31.87 | USD 0 | The current share valuation price of RARE based on adjusted close was USD 31.87. The average price that RARE shares were previous bought at was USD 36.4002. The current market price is -12.4% lower than average price they were purchased at. The value of the holding in RARE has fallen by USD 36,966 compared to the previous valuation of WISETFWTMRARETFP |
| RCKT - Rocket Pharmaceuticals Inc | HOLD | 0 @ USD 3.32 | USD 0 | The current share valuation price of RCKT based on adjusted close was USD 3.32. The average price that RCKT shares were previous bought at was USD 5.1648. The current market price is -35.7% lower than average price they were purchased at. The value of the holding in RCKT has increased by USD 2,049 compared to the previous valuation of Rocket Pharmaceuticals Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 644.19 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 644.19. The average price that REGN shares were previous bought at was USD 625.065. The current market price is 3.1% higher than average price they were purchased at. The value of the holding in REGN has increased by USD 1,078,513 compared to the previous valuation of Regeneron Pharmaceuticals Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| REPL - Replimune Group Inc | HOLD | 0 @ USD 8.58 | USD 0 | The current share valuation price of REPL based on adjusted close was USD 8.58. The average price that REPL shares were previous bought at was USD 8.8653. The current market price is -3.2% lower than average price they were purchased at. The value of the holding in REPL has fallen by USD 19,930 compared to the previous valuation of Replimune Group Inc |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 11.61 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 11.61. The average price that RGNX shares were previous bought at was USD 9.09605. The current market price is 27.6% higher than average price they were purchased at. The value of the holding in RGNX has increased by USD 1,679 compared to the previous valuation of Regenxbio Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 6.55 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 6.55. The average price that RLAY shares were previous bought at was USD 4.10398. The current market price is 59.6% higher than average price they were purchased at. The value of the holding in RLAY has fallen by USD 34,171 compared to the previous valuation of Relay Therapeutics Inc |
| RNA - Avidity Biosciences Inc | HOLD | 0 @ USD 69.8 | USD 0 | The current share valuation price of RNA based on adjusted close was USD 69.8. The average price that RNA shares were previous bought at was USD 36.0618. The current market price is 93.6% higher than average price they were purchased at. The value of the holding in RNA has fallen by USD 2,483 compared to the previous valuation of Avidity Biosciences Inc |
| ROIV - Roivant Sciences Ltd | HOLD | 0 @ USD 20.23 | USD 0 | The current share valuation price of ROIV based on adjusted close was USD 20.23. The average price that ROIV shares were previous bought at was USD 12.6089. The current market price is 60.4% higher than average price they were purchased at. The value of the holding in ROIV has increased by USD 158,145 compared to the previous valuation of Roivant Sciences Ltd however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 40.42 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 40.42. The average price that RPRX shares were previous bought at was USD 35.4267. The current market price is 14.1% higher than average price they were purchased at. The value of the holding in RPRX has increased by USD 717,467 compared to the previous valuation of Royalty Pharma Plc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| RVMD - Revolution Medicines Inc | HOLD | 0 @ USD 59.34 | USD 0 | The current share valuation price of RVMD based on adjusted close was USD 59.34. The average price that RVMD shares were previous bought at was USD 40.834. The current market price is 45.3% higher than average price they were purchased at. The value of the holding in RVMD has increased by USD 93,090 compared to the previous valuation of Revolution Medicines Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 4.96 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 4.96. The average price that RXRX shares were previous bought at was USD 5.81039. The current market price is -14.6% lower than average price they were purchased at. The value of the holding in RXRX has fallen by USD 11,109 compared to the previous valuation of Recursion Pharmaceuticals Inc |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 99.47 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 99.47. The average price that RYTM shares were previous bought at was USD 74.8725. The current market price is 32.9% higher than average price they were purchased at. The value of the holding in RYTM has fallen by USD 237,128 compared to the previous valuation of Rhythm Pharmaceuticals Inc |
| SANA - Sana Biotechnology Inc | HOLD | 0 @ USD 4.08 | USD 0 | The current share valuation price of SANA based on adjusted close was USD 4.08. The average price that SANA shares were previous bought at was USD 3.20526. The current market price is 27.3% higher than average price they were purchased at. The value of the holding in SANA has fallen by USD 11,750 compared to the previous valuation of Sana Biotechnology Inc |
| SIGA - SIGA Technologies Inc | HOLD | 0 @ USD 8.43 | USD 0 | The current share valuation price of SIGA based on adjusted close was USD 8.43. The average price that SIGA shares were previous bought at was USD 6.81697. The current market price is 23.7% higher than average price they were purchased at. The value of the holding in SIGA has increased by USD 13,043 compared to the previous valuation of SIGA Technologies Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| SMMT - Summit Therapeutics PLC | HOLD | 0 @ USD 18.07 | USD 0 | The current share valuation price of SMMT based on adjusted close was USD 18.07. The average price that SMMT shares were previous bought at was USD 21.5764. The current market price is -16.3% lower than average price they were purchased at. The value of the holding in SMMT has increased by USD 278,267 compared to the previous valuation of Summit Therapeutics PLC however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| SNDX - Syndax Pharmaceuticals Inc | HOLD | 0 @ USD 15.1 | USD 0 | The current share valuation price of SNDX based on adjusted close was USD 15.1. The average price that SNDX shares were previous bought at was USD 11.5137. The current market price is 31.1% higher than average price they were purchased at. The value of the holding in SNDX has fallen by USD 13,759 compared to the previous valuation of Syndax Pharmaceuticals Inc |
| SNY - Sanofi ADR | HOLD | 0 @ USD 49 | USD 0 | The current share valuation price of SNY based on adjusted close was USD 49. The average price that SNY shares were previous bought at was USD 49.98. The current market price is -2.0% lower than average price they were purchased at. The value of the holding in SNY has fallen by USD 19,066 compared to the previous valuation of Sanofi ADR |
| SPRY - Silverback Therapeutics Inc | HOLD | 0 @ USD 9.05 | USD 0 | The current share valuation price of SPRY based on adjusted close was USD 9.05. The average price that SPRY shares were previous bought at was USD 13.9065. The current market price is -34.9% lower than average price they were purchased at. The value of the holding in SPRY has increased by USD 21,236 compared to the previous valuation of Silverback Therapeutics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| SRRK - Scholar Rock Holding Corp | HOLD | 0 @ USD 27.99 | USD 0 | The current share valuation price of SRRK based on adjusted close was USD 27.99. The average price that SRRK shares were previous bought at was USD 35.0637. The current market price is -20.2% lower than average price they were purchased at. The value of the holding in SRRK has fallen by USD 3,733 compared to the previous valuation of Scholar Rock Holding Corp |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 22.82 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 22.82. The average price that STOK shares were previous bought at was USD 15.4471. The current market price is 47.7% higher than average price they were purchased at. The value of the holding in STOK has fallen by USD 90,011 compared to the previous valuation of Stoke Therapeutics Inc |
| STRO - Sutro Biopharma | HOLD | 0 @ USD 0.984093 | USD 0 | The current share valuation price of STRO based on adjusted close was USD 0.984093. The average price that STRO shares were previous bought at was USD 0.901103. The current market price is 9.2% higher than average price they were purchased at. The value of the holding in STRO has fallen by USD 1,810 compared to the previous valuation of Sutro Biopharma |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 47.11 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 47.11. The average price that SUPN shares were previous bought at was USD 37.1482. The current market price is 26.8% higher than average price they were purchased at. The value of the holding in SUPN has fallen by USD 361,094 compared to the previous valuation of Supernus Pharmaceuticals Inc |
| SVRA - Savara Inc | HOLD | 0 @ USD 4.03 | USD 0 | The current share valuation price of SVRA based on adjusted close was USD 4.03. The average price that SVRA shares were previous bought at was USD 2.75495. The current market price is 46.3% higher than average price they were purchased at. The value of the holding in SVRA has fallen by USD 10,996 compared to the previous valuation of Savara Inc |
| SYRE - Spyre Therapeutics Inc. | HOLD | 0 @ USD 22.85 | USD 0 | The current share valuation price of SYRE based on adjusted close was USD 22.85. The average price that SYRE shares were previous bought at was USD 17.3459. The current market price is 31.7% higher than average price they were purchased at. The value of the holding in SYRE has fallen by USD 4,990 compared to the previous valuation of Spyre Therapeutics Inc. |
| TARS - Tarsus Pharmaceuticals Inc | HOLD | 0 @ USD 68.2 | USD 0 | The current share valuation price of TARS based on adjusted close was USD 68.2. The average price that TARS shares were previous bought at was USD 48.3869. The current market price is 40.9% higher than average price they were purchased at. The value of the holding in TARS has fallen by USD 90,543 compared to the previous valuation of Tarsus Pharmaceuticals Inc |
| TBPH - Theravance Biopharma Inc | HOLD | 0 @ USD 14.95 | USD 0 | The current share valuation price of TBPH based on adjusted close was USD 14.95. The average price that TBPH shares were previous bought at was USD 11.6119. The current market price is 28.7% higher than average price they were purchased at. The value of the holding in TBPH has increased by USD 6,438 compared to the previous valuation of Theravance Biopharma Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.06885. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| TNGX - Tango Therapeutics Inc | HOLD | 0 @ USD 7.50999 | USD 0 | The current share valuation price of TNGX based on adjusted close was USD 7.50999. The average price that TNGX shares were previous bought at was USD 6.10436. The current market price is 23.0% higher than average price they were purchased at. The value of the holding in TNGX has fallen by USD 35,520 compared to the previous valuation of Tango Therapeutics Inc |
| TRDA - Entrada Therapeutics Inc | HOLD | 0 @ USD 6.94001 | USD 0 | The current share valuation price of TRDA based on adjusted close was USD 6.94001. The average price that TRDA shares were previous bought at was USD 7.628. The current market price is -9.0% lower than average price they were purchased at. The value of the holding in TRDA has increased by USD 8,374 compared to the previous valuation of Entrada Therapeutics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| TSHA - Taysha Gene Therapies Inc | HOLD | 0 @ USD 4.03 | USD 0 | The current share valuation price of TSHA based on adjusted close was USD 4.03. The average price that TSHA shares were previous bought at was USD 2.8472. The current market price is 41.5% higher than average price they were purchased at. The value of the holding in TSHA has fallen by USD 41,851 compared to the previous valuation of Taysha Gene Therapies Inc |
| TVTX - Travere Therapeutics Inc | HOLD | 0 @ USD 33.72 | USD 0 | The current share valuation price of TVTX based on adjusted close was USD 33.72. The average price that TVTX shares were previous bought at was USD 19.3242. The current market price is 74.5% higher than average price they were purchased at. The value of the holding in TVTX has fallen by USD 23,331 compared to the previous valuation of Travere Therapeutics Inc |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 31.52 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 31.52. The average price that TWST shares were previous bought at was USD 36.4647. The current market price is -13.6% lower than average price they were purchased at. The value of the holding in TWST has increased by USD 56,280 compared to the previous valuation of Twist Bioscience Corp however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 13.49 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 13.49. The average price that TXG shares were previous bought at was USD 12.0295. The current market price is 12.1% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 9,603 compared to the previous valuation of 10X Genomics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| TXG - Terex Corporation | HOLD | 0 @ USD 13.49 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 13.49. The average price that TXG shares were previous bought at was USD 12.0295. The current market price is 12.1% higher than average price they were purchased at. The value of the holding in TXG has increased by USD 9,603 compared to the previous valuation of Terex Corporation however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| URGN - UroGen Pharma Ltd | HOLD | 0 @ USD 19.31 | USD 0 | The current share valuation price of URGN based on adjusted close was USD 19.31. The average price that URGN shares were previous bought at was USD 14.5512. The current market price is 32.7% higher than average price they were purchased at. The value of the holding in URGN has fallen by USD 15,316 compared to the previous valuation of UroGen Pharma Ltd |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 447.45 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 447.45. The average price that UTHR shares were previous bought at was USD 338.983. The current market price is 32.0% higher than average price they were purchased at. The value of the holding in UTHR has increased by USD 295,332 compared to the previous valuation of United Therapeutics Corporation however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| VCEL - Vericel Corp Ord | HOLD | 0 @ USD 37.2 | USD 0 | The current share valuation price of VCEL based on adjusted close was USD 37.2. The average price that VCEL shares were previous bought at was USD 40.7916. The current market price is -8.8% lower than average price they were purchased at. The value of the holding in VCEL has increased by USD 30,609 compared to the previous valuation of Vericel Corp Ord however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 46.04 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 46.04. The average price that VCYT shares were previous bought at was USD 30.8591. The current market price is 49.2% higher than average price they were purchased at. The value of the holding in VCYT has increased by USD 508,341 compared to the previous valuation of Veracyte Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| VERA - Vera Therapeutics Inc | HOLD | 0 @ USD 24.1 | USD 0 | The current share valuation price of VERA based on adjusted close was USD 24.1. The average price that VERA shares were previous bought at was USD 26.751. The current market price is -9.9% lower than average price they were purchased at. The value of the holding in VERA has fallen by USD 10,186 compared to the previous valuation of Vera Therapeutics Inc |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 5.4 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.4. The average price that VIR shares were previous bought at was USD 5.84108. The current market price is -7.6% lower than average price they were purchased at. The value of the holding in VIR has increased by USD 13,224 compared to the previous valuation of Vir Biotechnology Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| VIR - Vidrala S.A | HOLD | 0 @ USD 5.4 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 5.4. The average price that VIR shares were previous bought at was USD 5.84108. The current market price is -7.6% lower than average price they were purchased at. The value of the holding in VIR has increased by USD 13,224 compared to the previous valuation of Vidrala S.A however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 4.44 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 4.44. The average price that VNDA shares were previous bought at was USD 4.86392. The current market price is -8.7% lower than average price they were purchased at. The value of the holding in VNDA has increased by USD 3,682 compared to the previous valuation of Vanda Pharmaceuticals Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 417 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 417. The average price that VRTX shares were previous bought at was USD 414.932. The current market price is 0.5% higher than average price they were purchased at. The value of the holding in VRTX has fallen by USD 637,268 compared to the previous valuation of Vertex Pharmaceuticals Inc |
| VTRS - Viatris Inc | HOLD | 0 @ USD 10.75 | USD 0 | The current share valuation price of VTRS based on adjusted close was USD 10.75. The average price that VTRS shares were previous bought at was USD 9.55132. The current market price is 12.5% higher than average price they were purchased at. The value of the holding in VTRS has increased by USD 195,926 compared to the previous valuation of Viatris Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| VYGR - Voyager Therapeutics Inc | HOLD | 0 @ USD 4.27 | USD 0 | The current share valuation price of VYGR based on adjusted close was USD 4.27. The average price that VYGR shares were previous bought at was USD 3.83344. The current market price is 11.4% higher than average price they were purchased at. The value of the holding in VYGR has increased by USD 3,617 compared to the previous valuation of Voyager Therapeutics Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| WVE - Wave Life Sciences Ltd | HOLD | 0 @ USD 8.04 | USD 0 | The current share valuation price of WVE based on adjusted close was USD 8.04. The average price that WVE shares were previous bought at was USD 8.46109. The current market price is -5.0% lower than average price they were purchased at. The value of the holding in WVE has increased by USD 3,127 compared to the previous valuation of Wave Life Sciences Ltd however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| XENE - Xenon Pharmaceuticals Inc | HOLD | 0 @ USD 38.66 | USD 0 | The current share valuation price of XENE based on adjusted close was USD 38.66. The average price that XENE shares were previous bought at was USD 35.3894. The current market price is 9.2% higher than average price they were purchased at. The value of the holding in XENE has fallen by USD 21,535 compared to the previous valuation of Xenon Pharmaceuticals Inc |
| XERS - Xeris Pharmaceuticals Inc | HOLD | 0 @ USD 9.87 | USD 0 | The current share valuation price of XERS based on adjusted close was USD 9.87. The average price that XERS shares were previous bought at was USD 6.01947. The current market price is 64.0% higher than average price they were purchased at. The value of the holding in XERS has fallen by USD 3,188 compared to the previous valuation of Xeris Pharmaceuticals Inc |
| XNCR - Xencor Inc | HOLD | 0 @ USD 14.37 | USD 0 | The current share valuation price of XNCR based on adjusted close was USD 14.37. The average price that XNCR shares were previous bought at was USD 11.0407. The current market price is 30.2% higher than average price they were purchased at. The value of the holding in XNCR has increased by USD 30,535 compared to the previous valuation of Xencor Inc however if the holding was sold on 2025-11-05 this would crystalise an overall loss. |
| ZLAB - Zai Lab Ltd | HOLD | 0 @ USD 24.8 | USD 0 | The current share valuation price of ZLAB based on adjusted close was USD 24.8. The average price that ZLAB shares were previous bought at was USD 34.2542. The current market price is -27.6% lower than average price they were purchased at. The value of the holding in ZLAB has fallen by USD 33,292 compared to the previous valuation of Zai Lab Ltd |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 18.05 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 18.05. The average price that ZYME shares were previous bought at was USD 14.1821. The current market price is 27.3% higher than average price they were purchased at. The value of the holding in ZYME has fallen by USD 5,437 compared to the previous valuation of Zymeworks Inc. Common Stock |